Development and validation of RP-HPLC method for the determination of genotoxic alkyl benzenesulfonates in amlodipine besylate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 1, 2008, Pages 227-230

  Raman, N V V S S ^a   Reddy, K Ratnakar ^a   Prasad, A V S S ^a   Ramakrishna, K ^b  

^a Hetero Drugs Limited   (India)

^b GITAM UNIVERSITY   (India)

Author keywords

Alkyl benzenesulfonates; Amlodipine besylate; Development; Genotoxins; Validation

Indexed keywords

ACETONITRILE; ALKYLBENZENESULFONIC ACID; AMLODIPINE BESYLATE; ETHYLBENZENESULFONIC ACID; ISOPROPYLBENZENESULFONIC ACID; METHYLBENZENESULFONIC ACID; PHOSPHORIC ACID; PROPYLBENZENESULFONIC ACID; TRIETHYLAMINE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG DETERMINATION; DRUG IMPURITY; DRUG STRUCTURE; ELUTION; FLOW RATE; GENOTOXICITY; LIMIT OF DETECTION; LINEAR REGRESSION ANALYSIS; PARAMETER; PH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TABLET FORMULATION; VALIDATION PROCESS;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZENESULFONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GUIDELINES AS TOPIC; MOLECULAR STRUCTURE; MUTAGENS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 49949110106     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.05.021     Document Type: Article

References (14)

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use, S2 (R1); (2008).
2. European Medicines Agency, Evaluation of Medicines for Human Use, Guideline on the Limits of Genotoxic Impurities, CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006 (2007).
3. Indian Pharmacopoeia, The Indian Pharmacopoeia Commission, India, 2 (2007) 714-716.
4. United States Pharmacopeia, The United States Pharmacopeial Convention, Rockville, MD, 31 (2008) 1400-1401.
5. British Pharmacopoeia, The Department of Health, Great Britain, 1 (2008) 137-138.
6. European Pharmacopoeia, Council of Europe, France, 6 (2008) 1173-1175.
7. Glowienke S., Frieauff W., Allmendinger T., Martus H.J., Suter W., and Mueller L. Mutat. Res. 581 (2005) 23-34
8. Physicians Desk Reference, Thomson PDR, Montvale, NJ, 61 (2007) 2508-2514.
9. Alzaga R., Ryan R.W., Worth K.T., Lipczynski A.M., Szucs R., and Sandra P. J. Pharm. Biomed. Anal. 45 (2007) 472-479
10. Colon I., and Richoll S.M. J. Pharm. Biomed. Anal. 39 (2005) 477-485
11. Taylor G.E., Gosling M., and Pearce A. J. Chromatogr. A 1119 (2006) 231-237
12. Elder D.P., Teasdale A., and Lipczynski A.M. J. Pharm. Biomed. Anal. 46 (2008) 1-8
13. Ramakrishna K., Raman N.V.V.S.S., Narayana Rao K.M.V., Prasad A.V.S.S., and Subhaschander Reddy K. J. Pharm. Biomed. Anal. 46 (2008) 780-783
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1); (2005).